Compare ADMA Biologics Inc (ADMA) vs FuelCell Energy Inc (FCEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs FuelCell Energy Inc — how do they compare? ADMA Biologics Inc trades at $9.91 (market cap $2.22B), while FuelCell Energy Inc trades at $20.25 (market cap $1.54B). The key difference: ADMA Biologics Inc is the larger of the two by market cap, and FuelCell Energy Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | FCEL | |
|---|---|---|
Market Cap | $2.22B | $1.54B |
Sector | Health | Industrials |
52-Week High | $20.38 | $36.01 |
52-Week Low | $7.60 | $3.92 |
Enterprise Value | $2.29B | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
FuelCell Energy (FCEL) trades at $19.83, down 2.94% on the day, with a bearish technical signal and negative profitability metrics. The company reported a net loss of $187.90 million on $158.16 million revenue for 2025, though it beat EPS estimates in two recent quarters. Recent news highlights partnerships with Siemens and AI-driven power demand opportunities, contributing to volatile stock performance.
Outlook remains speculative with high risk due to persistent losses and negative margins, offset by analyst optimism (45% buy rating) and a $20.75 consensus price target. Key risks include cash burn, competitive pressures, and execution challenges in scaling hydrogen technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →
